HEMATOLOGY

Chronic Lymphocytic Leukemia

Stephan Grupp, MD, PhD, discusses updated findings from the phase II ELIANA trial of tisagenlecleucel (Kymriah), a chimeric antigen receptor T-cell therapy, in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high disease burden.

Jordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.

Eli Lilly and Company will acquire Loxo Oncology for an estimated $8 billion in cash, the company has announced.

Relapsed Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, discusses phase II findings with obinutuzumab, ibrutinib, and venetoclax and the future of dose-limited regimens in CLL.

In a merger agreement announced today, Bristol-Myers Squibb will be acquiring Celgene Corporation in a $74 billion deal to be paid with a combination of cash and stocks.

Dasatinib (Sprycel) tablets has been approved by the FDA to be used in combination with chemotherapy for the treatment of pediatric patients &ge;1 year of age with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.<br /> &nbsp;

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;December 2018, including several new approvals, an accelerated approval, and a priority review.

John P. Leonard, MD, discusses the primary results from the randomized, double-blind phase III AUGMENT trial investigating the combination lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with recurrent indolent lymphomas.

During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma

Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R² regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br /> &nbsp;

Ravulizumab-cwvz has been approved by the FDA as an injection treatment for&nbsp;adults with paroxysmal nocturnal hemoglobinuria, a rare blood disorder that leads to hemolysis.

Several oncology experts discuss the FDA approvals they found most significant in 2018.

A longer-acting version of calaspargase pegol-mknl has been approved by the FDA&nbsp;as a component of a multiagent chemotherapy regimen for pediatric and young adult patients aged 1 month to 21 years with acute lymphoblastic leukemia.

Tagraxofusp-erzs infusion has been approved by the FDA for the treatment of adult and pediatric patients, aged &ge;2 years, with blastic plasmacytoid dendritic cell neoplasm.